Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: CuttingEdge Bio who wrote (2890)	4/1/2020 10:41:57 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

Hydroxychloroquine with Zn may be good alternative, but this is for early onset of infection. Ance viral titer in lung reach large # , drug can not do much. For late stage..aggressive anti-viral cocktail may be option (test viral level as surrogate indicator of arm activity), point is that drug prevent subject entering critical end-stage! Than it is too late. If it is CRS (elevated IL-6 level) surrogate target, pts will not recover on its own. Maybe anti-complement, maybe immune-buster, something... Today, death US # reach +1000, in few days it will be +2500, sure we can learn drug activity without so many sacrifices? China report(s) indicate very clear medical benefit for Actemra...it is not by chance!